India has tightened its pharmaceutical regulations in a significant move aimed at strengthening patient safety and preventing the misuse of medicines. The Ministry of Health and Family Welfare has amended the country’s drug rules to ensure that syrup-based medicines, including widely used cough syrups, can no longer be purchased over the counter without a doctor’s prescription.
The decision comes amid heightened scrutiny of cough syrup safety following a series of alarming incidents involving contaminated medicines that were allegedly linked to the deaths of several children in different parts of the country. Health authorities believe stricter controls on the sale and distribution of such medicines will help improve oversight and reduce risks associated with inappropriate use.
Under the newly notified Drugs (Fifth Amendment) Rules, 2026, the Centre has removed the category “syrups” from Schedule K of the Drugs Rules, 1945. Schedule K contains a list of medicines that are exempt from certain regulatory requirements related to sale and distribution under specified conditions. With the amendment now in force, syrup-based formulations will no longer enjoy those exemptions and will require a valid prescription from a registered medical practitioner before being dispensed.
The notification, issued under the powers granted by Sections 12 and 33 of the Drugs and Cosmetics Act, 1940, marks one of the most notable regulatory changes in the pharmaceutical sector this year. Officials say the measure is intended to strengthen safeguards around medicines that are frequently used by children and vulnerable patients.
The decision arrives at a time when concerns over the safety of cough and cold medicines have intensified both within India and internationally. Public health experts have repeatedly warned against the indiscriminate use of cough syrups, particularly among young children, citing the risk of adverse reactions and the possibility of contamination in poorly regulated supply chains.
The government’s broader concern is reflected in the draft National Formulary of India (NFI) 2026, which recommends that cough and cold medications should neither be prescribed nor dispensed to children below two years of age. The draft also advises caution for children under five, stating that such medicines should be used only when there is a clear clinical necessity and under close medical supervision.
The latest regulatory change follows a series of tragic incidents that drew national attention to drug safety standards. Last year, reports emerged that contaminated cough syrups may have contributed to the deaths of multiple children in Madhya Pradesh and Rajasthan. The cases triggered widespread concern among parents, healthcare professionals and regulatory authorities.
Responding to the reports, the National Human Rights Commission (NHRC) intervened and issued notices to the governments of Madhya Pradesh, Rajasthan and Uttar Pradesh. The Commission expressed concern that the alleged incidents pointed to serious lapses in drug regulation, quality control and public health oversight.
Acting on complaints that linked the deaths of at least a dozen children to the consumption of suspected contaminated syrup, the NHRC directed state authorities to conduct immediate investigations. The Commission also called for extensive testing of medicine samples and ordered authorities to take urgent measures to curb the circulation of counterfeit and substandard pharmaceutical products.
The issue gained further international attention when the World Health Organization (WHO) issued a medical product alert concerning three India-manufactured cough syrups—Coldrif, Respifresh TR and ReLife. The global health body classified the products as substandard and urged regulators worldwide to remain vigilant if the medicines appeared within their markets.
The WHO warning was particularly significant because it followed reports of acute illnesses and child deaths associated with suspected kidney failure. According to health investigations cited by regulators, several affected children had reportedly consumed one of the identified syrup formulations before developing severe complications.
In its alert, the WHO urged countries to strengthen monitoring of pharmaceutical supply chains and increase surveillance of informal markets where counterfeit or poorly regulated medicines are often distributed. The organization emphasized that rapid detection and reporting of potentially harmful medicines are essential to preventing further loss of life.
India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), subsequently informed the WHO that tests had detected Diethylene Glycol (DEG) in at least three oral liquid medicines. DEG is a toxic industrial solvent that has been linked to multiple medicine-related poisoning incidents globally. Even small quantities can cause severe kidney damage, particularly in young children.
Following the discovery, state authorities reportedly halted production at the facilities connected to the medicines under investigation and suspended their manufacturing and marketing permissions pending further inquiry. Regulatory agencies also intensified inspections and quality checks across affected regions.
The crackdown has extended beyond manufacturing units. Authorities in Uttar Pradesh recently launched a Special Investigation Team (SIT) probe into the illegal trade of codeine-based cough syrups, resulting in multiple arrests. The operation highlighted concerns that cough syrups are not only vulnerable to contamination issues but are also susceptible to misuse and unauthorized distribution networks.
Healthcare experts say the requirement of a doctor’s prescription could help reduce both risks. By bringing syrup-based medicines under stricter medical supervision, authorities hope to ensure that patients receive appropriate treatment while also creating a clearer accountability trail for manufacturers, distributors and retailers.
For pharmacists and medical practitioners, the amendment is expected to alter routine dispensing practices. Pharmacies will now be required to verify prescriptions before selling cough syrups and other syrup formulations covered by the revised rule. While some industry stakeholders may raise concerns about accessibility, public health advocates argue that the long-term benefits of enhanced safety outweigh potential inconveniences.
IAF AN-32 Transport Aircraft Crashes During Landing at Jorhat Air Force Station in Assam, Investigation Underway
Read More
Isha Rikhi Confirms Marriage to Rapper Badshah After Months of Speculation
Read More
Vandana Gupta Occupies District Judge’s Chair in Varanasi Court, Sparks Hour-Long Drama Before Police Intervention
Read MoreThe government’s latest action signals a broader shift toward tighter regulation of medicines that have historically been easy to obtain without professional consultation. As investigations into contaminated pharmaceutical products continue and regulators face increasing pressure to strengthen quality controls, the prescription-only status of cough syrups represents a decisive step in rebuilding public confidence in drug safety.
For millions of Indian households accustomed to purchasing cough syrups directly from pharmacies, the change marks the beginning of a new regulatory era—one shaped by lessons learned from preventable tragedies and a renewed focus on protecting public health, especially the health of children.